Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 16/20 | 0.58 |
| ▸ | BCR | P11274 | 14/20 | 0.58 |
| ▸ | PRKCA | P17252 | 11/20 | 0.53 |
| ▸ | SRC | P12931 | 10/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 8/20 | 0.53 |
| ▸ | EGFR | P00533 | 4/20 | 0.53 |
| ▸ | PRKACA | P17612 | 1/20 | 0.53 |
| ▸ | PRKACG | P22612 | 1/20 | 0.53 |
| ▸ | PRKACB | P22694 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12837140 | 0.88 | ABL1 (0.58) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL8255847 | 0.86 | PIK3CG (0.59) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL11924749 | 0.84 | ABL1 (0.62) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL8252396 | 0.83 | ABL1 (0.77) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL8253620 | 0.82 | PRKCA (0.55) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL11929046 | 0.80 | ABL1 (0.53) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL8246547 | 0.78 | ABL1 (0.58) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL7476769 | 0.74 | ABL1 (1.00) | ABL1BCRPRKCASRCPRKCD | |
| SCHEMBL1684782 | 0.72 | CDK2 (0.77) | PIK3CAPIK3CGPKMKDR | |
| SCHEMBL6106194 | 0.72 | CDK2 (0.63) | ABL1BCRPRKCAPRKCDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501812-B2 | Therapeutic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2012-08-16 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | ABL1 1532/4885BCR 1892/4885PRKCA 159/4885 |
| US-20120208846-A1 | Therapeutic Methods For Type I Diabetes | MAPK9, IAPP, RNASE1 | ABL1 1532/4885BCR 1892/4885PRKCA 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.